Arabinonucleosides: Nucleosides containing arabinose as their sugar moiety.Drug Interactions: The action of a drug that may affect the activity, metabolism, or toxicity of another drug.Adenine NucleotidesLeukemia, Hairy Cell: A neoplastic disease of the lymphoreticular cells which is considered to be a rare type of chronic leukemia; it is characterized by an insidious onset, splenomegaly, anemia, granulocytopenia, thrombocytopenia, little or no lymphadenopathy, and the presence of "hairy" or "flagellated" cells in the blood and bone marrow.Antineoplastic Agents: Substances that inhibit or prevent the proliferation of NEOPLASMS.Consolidation Chemotherapy: Drug treatment designed to further diminish the disease toward complete remission following INDUCTION CHEMOTHERAPY. It helps to consolidate the gains during induction chemotherapy and may be followed by MAINTENANCE CHEMOTHERAPY.Cytarabine: A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)Multiple Sclerosis: An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)Trust: Confidence in or reliance on a person or thing.Pentostatin: A potent inhibitor of ADENOSINE DEAMINASE. The drug induces APOPTOSIS of LYMPHOCYTES, and is used in the treatment of many lymphoproliferative malignancies, particularly HAIRY CELL LEUKEMIA. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity.Multiple Sclerosis, Relapsing-Remitting: The most common clinical variant of MULTIPLE SCLEROSIS, characterized by recurrent acute exacerbations of neurologic dysfunction followed by partial or complete recovery. Common clinical manifestations include loss of visual (see OPTIC NEURITIS), motor, sensory, or bladder function. Acute episodes of demyelination may occur at any site in the central nervous system, and commonly involve the optic nerves, spinal cord, brain stem, and cerebellum. (Adams et al., Principles of Neurology, 6th ed, pp903-914)Leukemia, Lymphocytic, Chronic, B-Cell: A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.Multiple Sclerosis, Chronic Progressive: A form of multiple sclerosis characterized by a progressive deterioration in neurologic function which is in contrast to the more typical relapsing remitting form. If the clinical course is free of distinct remissions, it is referred to as primary progressive multiple sclerosis. When the progressive decline is punctuated by acute exacerbations, it is referred to as progressive relapsing multiple sclerosis. The term secondary progressive multiple sclerosis is used when relapsing remitting multiple sclerosis evolves into the chronic progressive form. (From Ann Neurol 1994;36 Suppl:S73-S79; Adams et al., Principles of Neurology, 6th ed, pp903-914)Cancer Care Facilities: Institutions specializing in the care of cancer patients.Comprehensive Health Care: Providing for the full range of personal health services for diagnosis, treatment, follow-up and rehabilitation of patients.Antimetabolites: Drugs that are chemically similar to naturally occurring metabolites, but differ enough to interfere with normal metabolic pathways. (From AMA Drug Evaluations Annual, 1994, p2033)Gout: Hereditary metabolic disorder characterized by recurrent acute arthritis, hyperuricemia and deposition of sodium urate in and around the joints, sometimes with formation of uric acid calculi.Ehlers-Danlos Syndrome: A heterogeneous group of autosomally inherited COLLAGEN DISEASES caused by defects in the synthesis or structure of FIBRILLAR COLLAGEN. There are numerous subtypes: classical, hypermobility, vascular, and others. Common clinical features include hyperextensible skin and joints, skin fragility and reduced wound healing capability.Blood Platelets: Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation.Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.Contusions: Injuries resulting in hemorrhage, usually manifested in the skin.Tablets: Solid dosage forms, of varying weight, size, and shape, which may be molded or compressed, and which contain a medicinal substance in pure or diluted form. (Dorland, 28th ed)Sclerosis: A pathological process consisting of hardening or fibrosis of an anatomical structure, often a vessel or a nerve.Antiretroviral Therapy, Highly Active: Drug regimens, for patients with HIV INFECTIONS, that aggressively suppress HIV replication. The regimens usually involve administration of three or more different drugs including a protease inhibitor.Time Factors: Elements of limited time intervals, contributing to particular results or situations.European Union: The collective designation of three organizations with common membership: the European Economic Community (Common Market), the European Coal and Steel Community, and the European Atomic Energy Community (Euratom). It was known as the European Community until 1994. It is primarily an economic union with the principal objectives of free movement of goods, capital, and labor. Professional services, social, medical and paramedical, are subsumed under labor. The constituent countries are Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, Netherlands, Portugal, Spain, Sweden, and the United Kingdom. (The World Almanac and Book of Facts 1997, p842)EuropeNewspapers: Publications printed and distributed daily, weekly, or at some other regular and usually short interval, containing news, articles of opinion (as editorials and letters), features, advertising, and announcements of current interest. (Webster's 3d ed)Journalism, Medical: The collection, writing, and editing of current interest material on topics related to biomedicine for presentation through the mass media, including newspapers, magazines, radio, or television, usually for a public audience such as health care consumers.Occupational Therapy: Skilled treatment that helps individuals achieve independence in all facets of their lives. It assists in the development of skills needed for independent living.Pharmacy Administration: The business and managerial aspects of pharmacy in its broadest sense.Formularies as Topic: Works about lists of drugs or collections of recipes, formulas, and prescriptions for the compounding of medicinal preparations. Formularies differ from PHARMACOPOEIAS in that they are less complete, lacking full descriptions of the drugs, their formulations, analytic composition, chemical properties, etc. In hospitals, formularies list all drugs commonly stocked in the hospital pharmacy.Formularies, Hospital: Formularies concerned with pharmaceuticals prescribed in hospitals.United States Food and Drug Administration: An agency of the PUBLIC HEALTH SERVICE concerned with the overall planning, promoting, and administering of programs pertaining to maintaining standards of quality of foods, drugs, therapeutic devices, etc.Drug Approval: Process that is gone through in order for a drug to receive approval by a government regulatory agency. This includes any required pre-clinical or clinical testing, review, submission, and evaluation of the applications and test results, and post-marketing surveillance of the drug.Biosimilar Pharmaceuticals: BIOLOGIC PRODUCTS that are imitations but not exact replicas of innovator products.Legislation, Drug: Laws concerned with manufacturing, dispensing, and marketing of drugs.Therapeutic Equivalency: The relative equivalency in the efficacy of different modes of treatment of a disease, most often used to compare the efficacy of different pharmaceuticals to treat a given disease.Drug Industry: That segment of commercial enterprise devoted to the design, development, and manufacture of chemical products for use in the diagnosis and treatment of disease, disability, or other dysfunction, or to improve function.Pregnancy: The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.Pharmacists: Those persons legally qualified by education and training to engage in the practice of pharmacy.Double-Blind Method: A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment.Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Clinical Trials as Topic: Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.Drug Therapy, Combination: Therapy with two or more separate preparations given for a combined effect.Cladribine: An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia.Leukemia, Plasma Cell: A rare, aggressive variant of MULTIPLE MYELOMA characterized by the circulation of excessive PLASMA CELLS in the peripheral blood. It can be a primary manifestation of multiple myeloma or develop as a terminal complication during the disease.Leukemia: A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)Splenectomy: Surgical procedure involving either partial or entire removal of the spleen.Antibodies, Monoclonal, Murine-Derived: Antibodies obtained from a single clone of cells grown in mice or rats.Neoplasm, Residual: Remnant of a tumor or cancer after primary, potentially curative therapy. (Dr. Daniel Masys, written communication)Antibody-Dependent Cell Cytotoxicity: The phenomenon of antibody-mediated target cell destruction by non-sensitized effector cells. The identity of the target cell varies, but it must possess surface IMMUNOGLOBULIN G whose Fc portion is intact. The effector cell is a "killer" cell possessing Fc receptors. It may be a lymphocyte lacking conventional B- or T-cell markers, or a monocyte, macrophage, or polynuclear leukocyte, depending on the identity of the target cell. The reaction is complement-independent.Remission Induction: Therapeutic act or process that initiates a response to a complete or partial remission level.

Treatment of mantle-cell lymphomas with intermittent two-hour infusion of cladribine as first-line therapy or in first relapse. (1/220)

PURPOSE: Cladribine (2-chlorodeoxyadenosine, 2-CdA) has been reported to be effective in the treatment of low-grade lymphomas. The objective of this multicenter study was to evaluate the activity of cladribine in mantle-cell lymphomas as first-line therapy or in first relapse using an intermittent two-hour infusion of cladribine. PATIENTS AND METHODS: A total of 47 courses, or an average of four courses per patient, were administered to 12 patients (seven untreated, five relapsed) with 5 mg/m2 cladribine given as an intermittent two-hour infusion over five consecutive days for a maximum of six cycles every four weeks. RESULTS: Cladribine showed activity in patients with mantle-cell lymphomas, achieving a response rate of 58% (95% confidence interval (95% CI): 28%-85%). Myelosuppression was the major toxicity with 17% of grade 3 and 4 neutropenia. Thrombocytopenia was rare with only 2% of grade 3 and 4. CONCLUSION: These results demonstrate single-agent activity of cladribine in mantle-cell lymphomas using the intermittent two-hour infusion dosage regimen. To further improve treatment results, cladribine should be combined with other agents active in mantle-cell lymphomas.  (+info)

Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications. (2/220)

BACKGROUND AND OBJECTIVE: It has been widely demonstrated that one single 7-day course continuous infusion (c.i.) 2-chlorodeoxyadenosine (2-CdA) at a dose of 0.1 mg/kg daily is dramatically effective in inducing high and prolonged complete remission (CR) rates in patients with hairy-cell leukemia (HCL). However, 2-CdA administration often results in severe neutropenia and lymphocytopenia both responsible for the infectious complications observed in these patients. We previously reported preliminary data regarding the effectiveness and toxicity of a modified protocol of 2-CdA administration (0.15 mg/kg 2 hours infusion once a week for 6 courses) in 25 HCL patients. This treatment schedule produced a similar overall response rate compared to standard 2-CdA regimen and appeared to be followed by a lower incidence of infectious episodes. In the present study we report response rate and toxicity of weekly 2CdA administration in a larger cohort of patients and with a longer follow-up. DESIGN AND METHODS: In a group of HCL patients with a pronounced decrease in neutrophils count (< 1 x 10(9)/L), we modified the standard protocol (0.1 mg/kg daily x 7 days c.i.) by administering 2-CdA at a dose of 0.15 mg/kg 2 hours infusion once a week for 6 courses. Thirty HCL patients, 24 males and 6 females with a median age of 56 years (range 37-76), entered into this protocol. Seventeen out of 30 patients were at diagnosis while the remaining 13 had been previously treated with alpha-interferon (alpha-IFN) (7), or 2-CdA (4) or deoxycoformycin (DCF) (2). RESULTS: Overall, 22/30 (73%) patients achieved CR and 8 (27%) partial remission (PR) with a median duration of response at the time of writing of 35 months, ranging from 6 to 58 months. Five patients (1 CR and 4 PR) have so far progressed. The treatment was very well tolerated. Five out of 30 patients (16%) developed severe neutropenia (neutrophils < 0.5 x 10(9)/L) and only in two of them we did register an infectious complication which required treatment with systemic antibiotics and granulocyte colony-stimulating factor (G-CSF). INTERPRETATION AND CONCLUSIONS: In conclusion, we confirm that weekly administration of 2-CdA at a dose of 0.15 mg/kg for 6 courses appears to be very effective in HCL inducing a high CR rate, similar to that observed with daily c.i. administration. CR durability and relapse/progression rates are also comparable to standard 2-CdA schedule. Moreover this new regimen seems to be safer in pancytopenic patients, markedly reducing life-threatening infectious complications.  (+info)

Cladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative malignancies. (3/220)

The feasibility of combining cladribine with cyclophosphamide and prednisone in the management of indolent lymphoid malignancies was determined. Nineteen patients [nine chronic lymphocytic leukaemia (CLL), seven non-Hodgkin's lymphoma (NHL) and three macroglobulinaemia (M))] received cladribine 0.1 mg kg(-1) per day as a subcutaneous bolus injection on days 1-3 (up to 5 injections) with intravenous cyclophosphamide 500 mg m(-2) on day 1 and oral prednisone 40 mg (m-2) on days 1-5 at 4-weekly intervals up to a maximum of six courses. A total of 80 courses were given. Overall response rate was 88%, with four patients achieving a complete clinical and haematological response and 12 achieving a partial response. Neutropenia WHO grade 4 in two patients and WHO grade 3 infection in one patient were the limiting toxicities on treatment. During the follow-up, WHO grade >3 haematological complications occurred in five patients and WHO grade >3 non-haematological complications in five patients. There were no treatment-related deaths. This study demonstrates the feasibility of the cladribine/cyclophosphamide/prednisone (CCP) combination that appears highly active and safe in the management of indolent lymphoid malignancies.  (+info)

Filgrastim for cladribine-induced neutropenic fever in patients with hairy cell leukemia. (4/220)

Cladribine treatment of hairy cell leukemia (HCL) is complicated by neutropenic fever in 42% of patients despite documented infections being relatively uncommon. We performed a study of priming filgrastim followed by cladribine and then filgrastim again to determine if filgrastim would lead to a reduction of neutropenia and febrile episodes. Thirty-five patients received filgrastim and cladribine and were compared with 105 historic controls treated with cladribine alone. Cladribine was administered at 0.1 mg/kg/d by continuous infusion for 7 days. Filgrastim was administered at 5 micrograms/kg/d subcutaneously on days -3, -2, and -1 and then again after the completion of cladribine until the absolute neutrophil count (ANC) was >/=2 x 10(9)/L on 2 consecutive days (days +8, +9, etc). After filgrastim priming, the median ANC increased from 0.9 x 10(9)/L to 2.26 x 10(9)/L (2.5-fold increase), and after cladribine, the median nadir ANC in the filgrastim-treated group was 0.53 x 10(9)/L compared with 0.29 x 10(9)/L among historic controls (P =. 04). The median number of days to an ANC greater than 1.0 x 10(9)/L was 9 days in the filgrastim-treated group versus 22 days among historic controls (P < 10(-5)). The percentage of febrile patients, number of febrile days, and frequency of admissions for antibiotics were not statistically different in the two groups. Filgrastim regularly increases the ANC in patients with HCL and shortens the duration of severe neutropenia after cladribine. This phase II study, with comparison to historical controls, failed to detect any clinical advantage from the use of filgrastim and cladribine in the treatment of HCL. Accordingly, the routine adjunctive use of filgrastim with cladribine in the treatment of HCL cannot be recommended.  (+info)

Cladribine activity in adult langerhans-cell histiocytosis. (5/220)

Langerhans-cell histiocytosis (LCH) results from the accumulation of tissue histiocytes derived from the same progenitor cells as monocytes. Because cladribine is potently toxic to monocytes, we conducted a phase II trial of cladribine. Cladribine was administered to 13 LCH patients at 0.14 mg/kg per day by 2-hour intravenous infusion for 5 consecutive days, every 4 weeks for a maximum of six courses. Median age was 42 years (range, 19 to 72) and median pretreatment disease duration was 99 months (range, 6 to 252). One patient was untreated, one had received prior prednisone only, one prior radiation only, six prior radiation and chemotherapy, and four prior surgery, radiation, and chemotherapy. Seven patients had cutaneous involvement, six multifocal osseous, six pulmonary, two each with soft tissue and nodal involvement, and four had diabetes insipidus. Of 13 patients, 12 were evaluable for response and all for toxicity. After a median of three courses (range, 1 to 6), seven (58%) patients achieved complete responses (two pathologic and five clinical) and two (17%) patients achieved partial responses; overall response rate, 75%. Median response follow-up duration was 33 months (range, 1 to 65). Seven patients experienced grade 3 to 4 neutropenia. Only one patient had a documented infection, dermatomal herpes zoster. At a median follow-up of 42 months (range, 5 to 76), 12 patients remain alive and one patient has died. Thus, cladribine has major activity in adult LCH and warrants further investigation in both pediatric and adult LCH as a single agent and in combination with other drugs.  (+info)

Basic fibroblast growth factor is expressed by CD19/CD11c-positive cells in hairy cell leukemia. (6/220)

Several features are characteristic for hairy cell leukemia (HCL). Among those are pancytopenia, bone marrow fibrosis, and the appearance of a defined tumor cell phenotype in peripheral blood (PB), bone marrow (BM), and spleen. Hairy cells (HC) coexpress antigens specific for B lymphocytes and monocytes/macrophages and thus the malignant cell does not seem to be restricted to a defined lineage. When serum or bone marrow aspirate was screened by enzyme-linked immunosorbent assay (ELISA) for basic fibroblast growth factor (bFGF), specimen derived from HCL (serum: mean value, 29 pg/mL; BM aspirate: mean value, 641 pg/mL) contained significantly higher levels than those from healthy subjects. To study whether peripheral blood mononuclear cells (PBMC) derived from patients suffering from HCL and healthy donors (HD) were capable of producing bFGF, culture supernatant (conditioned medium, [CM]) was tested for the presence of this cytokine. While bFGF was not detectable in cell cultures from HD, HCL-derived CM contained relatively high levels of bFGF. CM was successfully used for stimulation of mesenchymal cell proliferation, which could be inhibited by a neutralizing anti-bFGF antibody. Cellular activation by pokeweed mitogen (PWM) or the combination of 12-o-tetradecanoyl-phorbol-13-acetate (TPA) plus calcium ionophore (Ca-Ip) led to an enhanced mRNA expression. Results of Western blot experiments showed that HC synthesize at least three isoforms (approximately 18, 23, and 25 kD), but only the 23-kD isoform is exported. To assess the nature of the producer cell, double immunofluorescence analysis using a bFGF-specific and an anti-CD11c monoclonal antibody (MoAb) was undertaken. The majority of cells scoring positive for CD11c were also reactive with the anti-bFGF MoAb. Furthermore, enrichment of CD19/CD11c-positive cells correlated with enhanced bFGF levels, thereby supporting the argument for HC being the producer cells of bFGF. A biological function of bFGF in HCL might be mediation of chemoresistance, as 2-chlorodeoxyadenosine (2-CdA)-induced inhibition of cell proliferation can be reversed by bFGF. Endogenous bFGF production by HC is not affected by this purine analogue and 2-CdA-induced apoptosis is diminished in bFGF-producing HC as compared with normal PBMC. Therefore, bFGF expression by HC might be important for resistance to chemotherapy and survival of the malignant cells.  (+info)

Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse. (7/220)

The purine nucleoside analogues 2-chlorodeoxyadenosine (2-CdA) and 2'-deoxycoformycin (2'-DCF) induce complete remission (CR) in the majority of patients with hairy cell leukemia. However, minimal residual disease (MRD) has been detected in bone marrow core biopsies using immunohistochemical techniques in patients achieving CR by conventional criteria. This study was designed to compare the prevalence of MRD with each agent in patients in CR by using conventional criteria and the relapse-free survival for patients with and without MRD. Bone marrow biopsies from 39 patients treated with a single cycle of 2-CdA and 27 patients treated with multiple cycles of 2'-DCF were studied. The monoclonal antibodies anti-CD20, DBA.44, and anti-CD45RO were used to evaluate the paraffin-embedded bone marrow core biopsies for MRD. Five of 39 patients (13%) treated with 2-CdA had MRD, as compared to 7 of 27 patients (26%) treated with 2'-DCF (two-tailed P = 0.21). Relapse has occurred in two of the five patients with MRD after 2-CdA treatment and in four of the seven patients with MRD after 2'-DCF treatment. In total, 6 of the 12 patients (50%) with MRD have relapsed, whereas 3 of 54 patients (6%) without MRD have relapsed, and 2 patients have died without evidence of relapse. The estimated 4-year relapse-free survival among patients with MRD is 55% (+/- 15%, SE), compared to 88% (+/- 5%, SE) among patients without MRD (two-tailed P = 0.0023). The prevalence of MRD detected in a subset of patients in CR after either 2-CdA or 2'-DCF treatment did not differ significantly. However, the presence of MRD is associated with an increased risk of relapse.  (+info)

Biochemical pharmacology and resistance to 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine, a novel analogue of cladribine in human leukemic cells. (8/220)

The objective of the present study was to investigate the biochemical pharmacology of 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine (CAFdA)--a fluorinated analogue of cladribine [2-chloro-2'-deoxyadenosine, Leustatin (CdA)] with improved acid and metabolic stability--in human leukemic cell lines and in mononuclear cells isolated from patients with chronic lymphocytic leukemia (CLL) and acute myelocytic leukemia (AML). We have also made and characterized two cell lines that are not sensitive to the growth inhibitory and cytotoxic effects of CAFdA. Incubation of cells isolated from the blood of CLL and AML patients with various concentrations of CdA or of CAFdA accumulated CdA and CAFdA nucleotides in a dose-dependent manner. A significantly higher rate of phosphorylation to monophosphates was observed for CAFdA than for CdA in cells from CLL patients (n = 14; P = 0.04). The differences in the phosphorylation were even more pronounced for the respective triphosphates in both CLL (n = 14; P = 0.001) and AML (n = 4; P = 0.04) cells. Retention of CAFdA 5'-triphosphate (CAFdATP) was also longer than that for CdA 5'-triphosphate (CdATP) in cells from leukemic patients. The relative efficacy of CAFdA as a substrate for purified recombinant deoxycytidine kinase (dCK), the key enzyme in the activation of nucleoside analogues, was very high and exceeded that of CdA as well as the natural substrate, deoxycytidine, by a factor of 2 and 8, respectively. The Km for CAFdA with dCK was also lower than that for CdA, as measured in crude extracts from the human acute lymphoblastic leukemia cell line CCRF-CEM and the promyelocytic leukemia cell line HL60. Acquired resistance to CAFdA in HL60 and in CCRF-CEM cell lines was directly correlated to the decreased activity of the nucleoside phosphorylating enzyme, dCK. Resistant cells also showed a considerable degree of cross-resistance to analogues that were activated by dCK. These observations demonstrated that dCK phosphorylates CAFdA more efficiently than CdA. Furthermore, CAFdATP is apparently more stable than CdATP and the mechanisms of resistance to CAFdA are similar to those leading to CdA resistance. These results encourage studies on the clinical effect of CAFdA in lymphoproliferative diseases.  (+info)

*Cladribine

... is activated only by lymphocytes, and non-activated cladribine is removed quickly from all other cells. This means ... Cladribine is used for as a first and second-line treatment for symptomatic hairy cell leukemia and for B-cell chronic ... Cladribine, sold under the brand name Leustatin among others, is a medication used to treat hairy cell leukemia (HCL, leukemic ... Ivax to Develop Cladribine for Multiple Sclerosis Jennifer Bayot for the New York Times. July 26, 2005 Teva to Acquire Ivax, ...

*List of antineoplastic agents

Robak, Tadeusz; Korycka, Anna; Robak, Ewa (2005-12-31). "Older and New Formulations of Cladribine. Pharmacology and Clinical ... Hentosh, Patricia; Peffley, Dennis M. (2010-01-01). "The cladribine conundrum: deciphering the drug's mechanism of action". ... Bryson, Harriet M.; Sorkin, Eugene M. (1993-11-01). "Cladribine". Drugs. 46 (5): 872-894. doi:10.2165/00003495-199346050-00007 ... "Cladribine: not just another purine analogue?". Expert Opinion on Investigational Drugs. 18 (8): 1169-1181. doi:10.1517/ ...

*Sarcoidosis

... cladribine, chlorambucil, and cyclosporine), immunomodulatory (pentoxifylline and thalidomide), and anti-tumor necrosis factor ... "Treatment of Refractory Neurosarcoidosis with Cladribine" (PDF). New England Journal of Medicine. 350 (17): 1798-1799. doi: ...

*Multiple sclerosis research

For example, Cladribine (under development by Merck Serono; anticipated brand name: Movectro) is a antineoplastic oral drug ... Merck KGaA Submits Application For Cladribine Tablets As Multiple Sclerosis Therapy In Europe [2] Hope for MS pill after ... In January 2010, researchers published in NEJM significant results of cladribine use in reducing relapsing course of multiple ... An oral version of cladribine is in phase III. The completion of the phase III program took place in early 2009 meeting its ...

*Management of multiple sclerosis

Another oral drug, cladribine, was approved in Russia and Australia in 2010. Its application was rejected by the FDA and EMEA ... Comi, G; Hartung, HP; Kurukulasuriya, NC; Greenberg, SJ; Scaramozza, M (January 2013). "Cladribine tablets for the treatment of ...

*Erdheim-Chester disease

"Treatment of Erdheim-Chester disease with cladribine: A rational approach". British Journal of Ophthalmology. 88 (6): 844-7. ...

*Mantle cell lymphoma

Cladribine and clofarabine are two other drugs being investigated in MCL. A relatively new regimen that uses old drugs is PEP-C ...

*Enteropathy-associated T-cell lymphoma

2006). "Cladribine therapy in refractory celiac disease with aberrant T cells". Clin. Gastroenterol. Hepatol. 4 (11): 1322-7; ...

*Gluten-sensitive enteropathy-associated conditions

2006). "Cladribine therapy in refractory celiac disease with aberrant T cells". Clin. Gastroenterol. Hepatol. 4 (11): 1322-1327 ...

*Leukemia

Saven, A; Burian, C; Adusumalli, J; Koziol, J. A. (1999). "Filgrastim for cladribine-induced neutropenic fever in patients with ... In resistant cases, single-agent treatments with nucleoside drugs such as fludarabine, pentostatin, or cladribine may be ... Typical treatment approach Patients who need treatment usually receive either one week of cladribine, given daily by ... "Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: Final report from the Polish Adult ...

*CD22

"BL22 Immunotoxin in Treating Patients Previously Treated With Cladribine for Hairy Cell Leukemia". ClinicalTrials.gov - U.S. ...

*Ernest Beutler

Trans Assoc Am Phys 92: 189-195, 1979 Beutler E. Cladribine (2-chlorodeoxyadenosine). Lancet 340: 952-956, 1992 Feder JN, et al ...

*Chemotherapy

The deoxynucleoside analogues include cytarabine, gemcitabine, decitabine, azacitidine, fludarabine, nelarabine, cladribine, ...

*Adenosine deaminase

Cladribine is an anti-neoplastic agent used in the treatment of hairy cell leukemia; its mechanism of action is inhibition of ...

*Purine analogue

Pentostatin and cladribine are adenosine analogs that are used primarily to treat hairy cell leukemia. Purine Mercaptopurine ...

*Lymphocyte-variant hypereosinophilia

Recommended treatment includes chemotherapy with Fludarabine, Cladribine, or the CHOP combination of drugs followed by bone ...

*List of drugs: Cj-Cl

Cl-719 cladribine (INN) Claforan (Sanofi-Aventis), also known as cefotaxime clamidoxic acid (INN) Clamohexal (Hexal Australia ...

*Clofarabine

... a novel analogue of cladribine in human leukemic cells". Clin Cancer Res. 5 (9): 2438-44. PMID 10499616. Nagai S, Takenaka K, ...

*[email protected]

"Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single agent cladribine and with more ...

*Ribonucleotide reductase inhibitor

hydroxyurea fludarabine, cladribine, gemcitabine, tezacitabine, and triapine gallium maltolate, gallium nitrate Ribonucleotide ...

*Multiple sclerosis drug pipeline

Check date values in: ,date= (help) Cladribine approved in Europe, Press Release A Multiple Treatment Comparison of Eleven ... And this list has been recently joined by cladribine, but only in Europe by now. It is approved for highly active relapsing ...

*MALT lymphoma

The purine nucleoside analogs fludarabine and cladribine also demonstrate activity, the latter conferring a CR rate of 84% (100 ... in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type treated with cladribine ...

*ATC code L01

L01BA03 Raltitrexed L01BA04 Pemetrexed L01BA05 Pralatrexate L01BB02 Mercaptopurine L01BB03 Tioguanine L01BB04 Cladribine ...

*Antileukemic drug

6-Mercaptopurine 6-Thioguanine Aminopterin Arsenic trioxide Asparaginase Cladribine Clofarabine Cyclophosphamide Cytosine ...

*Scripps Research Institute

... for lupus Cladribine (Leustatin®) for hairy cell leukemia Purification of Factor VIII for hemophilia Tafamidis (Vyndaqel®) for ...
The targeted agent, Zelboraf® (vemurafenib), which is approved for the treatment of melanoma, provided high anti-cancer activity among patients with hairy-cell leukemia that had stopped responding to prior therapies. These results were recently published in the New England Journal of Medicine.. Hairy-cell leukemia is a type of cancer in which too many abnormal immune cells are produced. It is considered a slow-growing type of leukemia that occurs more commonly in older men. The cancer cells have a "hairy" appearance under the microscope.. A genetic mutation referred to as the BRAF V600E mutation is thought to be an involved the excessive replication of hairy cell leukemia, as it is a common mutation in this type of cancer. Zelboraf binds to a specific site in cells that blocks the excessive replication caused by the BRAF V600E mutation.. Researchers from Italy and the United States conducted clinical trials to evaluate Zelboraf among patients with hairy cell leukemia that had stopped responding ...
Symptoms of Hairy cell leukemia including 13 medical symptoms and signs of Hairy cell leukemia, alternative diagnoses, misdiagnosis, and correct diagnosis for Hairy cell leukemia signs or Hairy cell leukemia symptoms.
1. Cawley JC, Burns GF, Hayhoe FG. A chronic lymphoproliferative disorder with distinctive features: a distinct variant of hairy-cell leukaemia. Leuk Res. 1980;4(6):547-59 2. Matutes E, Wotherspoon A, Catovsky D. The variant form of hairy-cell leukaemia. Best Pract Res Clin Haematol. 2003;16(1):41-56 3. Robak T. Hairy-cell leukemia variant: recent view on diagnosis, biology and treatment. Cancer Treat Rev. 2011;37(1):3-10 4. Matutes E, Martínez-Trillos A, Campo E. Hairy cell leukaemia-variant: Disease features and treatment. Best Pract Res Clin Haematol. 2015;28(4):253-63 5. Jain P, Pemmaraju N, Ravandi F. Update on the biology and treatment options for hairy cell leukemia. Curr Treat Options Oncol. 2014;15(2):187-209 6. Swerdlow S, Campo E, Harris NL. et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (4th ed.). Lyon: International Agency for Research on Cancer (IARC). 2008:188-90 7. Tiacci E, Trifonov V, Schiavoni G, Holmes A, Kern W, Martelli MP. et al. BRAF ...
On September 13, the Food and Drug Administration approved moxetumomab pasudotox-tdfk (Lumoxiti, AstraZeneca) injection for intravenous use for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog. Lumoxiti is a CD22-directed cytotoxin and is the first of this type of treatment for patients with HCL ...
TY - JOUR. T1 - Activation of deoxycytidine kinase by inhibition of DNA synthesis in human lymphocytes. AU - Csapó, Z.. AU - Sasvári, M.. AU - Spasokoukotskaja, T.. AU - Talianidis, Iannis. AU - Eriksson, Staffan. AU - Staub, M.. PY - 2001/1/15. Y1 - 2001/1/15. N2 - Deoxycytidine kinase (dCK, EC.2.7.1.74) is a key enzyme in the intracellular metabolism of 2-chlorodeoxyadenosine, 1β-D-arabinofuranosylcytosine, difluorodeoxycytidine, and other drugs used in chemotherapy of different leukaemias and solid tumours. Recently, stimulation of dCK activity was shown by these analogues and by other genotoxic agents such as etoposide and NaF, all of which cause severe inhibition of DNA synthesis in cell cultures. Here we describe that direct inhibition of DNA polymerases by aphidicolin stimulated dCK activity in normal lymphocytes and acute myeloid leukaemic cells, as well as in HL 60 promyelocytic cell cultures. Increased dCK activity was not due to new protein synthesis under our conditions, as ...
Hairy cell leukemia is a rare type of cancer of blood which is caused due to abnormal growth of B cells. Hairy cell leukemia (HCL) is called so as the outg
What is Hairy Cell Leukemia? Get the facts about Hairy Cell Leukemia symptoms, testing, treatment and care options from trusted sources.
[Therapeutic aspects in the management of hairy cell leukemia].: We searched Medline, Pascal, and Current Contents for literature on the treatment of hairy cell
What is hairy cell leukemia - I had blood work done red blood cells white blood cells and platelets were all low also hemocrit among others does this indicate leukemia? Maybe. At your age, leukemia usually shows a high white count. However, anemia is ALWAYS serious and worth investigating. WBC and platelets values only somewhat out of range are less worrisome. Im betting we find something treatable.
Proliferation and cytogenetic analysis of hairy cell leukemia upon stimulation via the CD40 antigen.: Using the CD40 system, in vitro proliferation of hairy cel
Hairy Cell Leukemia Diagnosis (costs for program #144157) ✔ Academic Hospital Harlaching ✔ Department of Hematology, Oncology and Palliative Medicine ✔ BookingHealth.com
Hairy Cell Leukemia Diagnosis (costs for program #35009) ✔ Academic Hospital Nordwest ✔ Department of Oncology and Hematology ✔ BookingHealth.com
Reversine, a purine analog, experienced been proved that it could induce dedifferentiation of differentiated cells into multipotent progenitor cells. acid-Schiff staining assay in hepatogenic differentiated … Manifestation of pluripotent guns and epigenetic guns To further characterize the pluripotency of reversine-pretreated cells, manifestation of specific guns 468-28-0 supplier (April4, Sox2 and Nanog) of pluripotent cells were analyzed by using RT-PCR, western blotting and immunofluorescence. In addition, we also desired to determine which gene caused the differential strength. The outcomes indicated that reversine elevated the reflection of March4 significantly, but Sox2 and Nanog had been not really discovered (Fig. ?(Fig.5,5, A and B), which indicated the account activation of Oct4 performs a major function in order of 468-28-0 supplier cell pluripotency. Remarkably, upon reversine removal after 8 times, reversine-treated fibroblasts steadily came back to primary phenotype and the ...
FD65F7217BBE656C449A0090 Content-Type: text/plain; charset=us-ascii Content-Transfer-Encoding: 7bit Thank you very much for your comments, We are using: DBA.44 from Dako catalog # M880. No pretreatment. Primary antibody dilution of 1:15 for 2 hours at RT, detection on the Ventana using the basic DAB kit. TRAP from Zymed catalog # 18-0199. HIER in citrate buffer pH 6.0. Primary antibody dilution of 1:100 for 1 hour at RT, detection on the Ventana using the basic DAB kit. DBA 44 dose not work on NexES. If they do Antigen Retrieval and incubate off line 30 min 1:25 -1:50 it works ok. DAKO does carry a Hairy Cell Leukemia marker (M0880). We have not tested it on the NeXES, but it should work in theory. Please contact DAKO We use the DBA.44 clone from Dako with a citrate buffer pretreatment at a dilution of 1:50. I do not know about using on the Nexes, as I have no experience with that instrument. The only antibody of which I am aware for Hairy Cell Leukemia is is DBA-44 but I do not recommend it ...
Hairy cell leukemia is a cancer of the blood. In hairy cell leukemia bone marrow produces too many lymphocytes, a white blood cell. This disease is rare and has a slow progression. The name hairy cells is derived from the abnormal villi - fine projections from the surface of the lymphocytes. When the cells increase,…
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if giving cl
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market. ...
We offer clinical cancer updates, treatment guidance, and research news to the oncology nursing community. Visit us often for drug therapy testing results, patient care information and more. Download our FREE app today.
This page was last edited 18:00, 30 October 2015 by Haytham Allaham. Based on work by Kalsang Dolma, Lakshmi Gopalakrishnan, Michael Maddaleni, Varun Kumar, C. Michael Gibson, Jinhui Wu, Cafer Zorkun, Erin Lord and Jacki Buros (bot), wikidoc user and wikidoc anonymous user WhatamIdoing ...
(2-5)-3-deoxyadenosine triphosphate-3-deoxyadenosine monophosphate: dimers & trimers of the (p3dA) part of above cpd were also synthesized in first source
Burghaus L, Schütz U, Krempel U, De Vos RA, Jansen Steur EN, Wevers A, Lindstrom J, Schröder H. Quantitative assessment of nicotinic acetylcholine receptor proteins in the cerebral cortex of Alzheimer patients ...
Hairy cell leukemia is an uncommon hematological malignancy characterized by an accumulation of abnormal B lymphocytes. It is usually classified as a sub-type of chronic lymphocytic leukemia (CLL). Hairy cell leukemia makes up approximately 2% of all leukemias, with fewer than 2,000 new cases diagnosed annually in North America and Western Europe combined. Hairy cell leukemia was originally described as histiocytic leukemia, malignant reticulosis, or lymphoid myelofibrosis in publications dating back to the 1920s. The disease was formally named leukemic reticuloendotheliosis and its characterization significantly advanced by Bertha Bouroncle and colleagues at The Ohio State University College of Medicine in 1958. Its common name, which was coined in 1966, is derived from the "hairy" appearance of the malignant B cells under a microscope. In hairy cell leukemia, the "hairy cells" (malignant B lymphocytes) accumulate in the bone marrow, interfering with the production of normal white blood cells, ...
The initial therapies of choice for hairy cell leukemia are either cladribine (2-chlorodeoxyadenosine, 2-CdA) or pentostatin. [1] [2] These drugs have comparable response rates but have not been compared in phase III trials. Cladribine is administered as a one-time continuous infusion or series of subcutaneous injections and is associated with a high rate of febrile neutropenia. [3] [4] [5] [6] Rarely, more than one course of treatment is required to induce a desirable response. Treatment should be discontinued once complete remission or stable partial remission with normalization of peripheral blood counts is reached. The presence of residual disease may be predictive of relapse but does not seem to affect survival. [5] [7] The role of consolidation or maintenance therapy in preventing relapse or progression of the disease after treatment with purine analogs has not been evaluated and remains unproven. Pentostatin is administered intermittently for a longer time but may result in a lower ...
Rosai-Dorfman disease (RDD) or sinus histiocytosis with massive lymphadenopathy is a rare lymphoproliferative disorder of unknown etiology. The disease usually presents with painless lymphadenopathy with occasional extranodal involvement in various organs. We report a case of a 36-year-old man wit …
Approval of LUMOXITI, a first-in-class medicine for hairy cell leukemia, marks first new treatment option for patients in over 20 years. AstraZeneca and MedImmune, its global biologics research and development arm, announced today that the US Food and Drug Administration (FDA) has approved LUMOXITI™ (moxetumomab pasudotox-tdfk) for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog. LUMOXITI is not recommended in patients with severe renal impairment (CrCl ≤ 29 mL/min). The Phase III trial results demonstrated 75% (95% confidence interval [CI]: 64, 84) of patients receiving LUMOXITI achieved an overall response; 30% (95% CI: 20, 41) had a durable complete response.. Dave Fredrickson, Executive Vice-President, Global Head Oncology Business Unit, said: "Todays FDA approval of LUMOXITI represents a significant milestone for people living with hairy ...
To the Editor: Purine analogues, including cladribine (2-chlorodeoxyadenosine), are increasingly used in the treatment of Waldenstroms macroglobulinemia and other hematologic cancers. (1) Cladribine can cause profound immunosuppression, lymphopenia, and increased susceptibility to opportunistic infections. (2) We report on a patient with Waldenstroms macroglobulinemia in whom an Epstein-Barr virus (EBV)-associated diffuse large-cell lymphoma developed after treatment with cladribine. A 69-year-old woman received the diagnosis of Waldenstroms macroglobulinemia with IgM kappa in 1991. Because of the progression of the disease, treatment with standard doses of cladribine was initiated in June 1994 and repeated in August 1994. The patient had a remarkable response, with alleviation of her symptoms and more than 90 percent reduction of the serum paraprotein level. Five months after the completion of treatment with cladribine, pain developed in the right hip, and a right acetabular lytic lesion was ...
Background:. Hairy cell leukemia (HCL) is highly responsive to but not curable by cladribine (CdA). HCL responds to rituximab, which is not yet standard therapy for HCL.. Patients with the CD25-negative variant (HCLv) respond poorly to initial cladribine but do respond to rituximab in anecdotal reports.. Purine analogs cladribine and pentostatin have similar efficacy for HCL, both inhibiting DNA synthesis selectively in HCL cells. Cladribine is effective after just 1 cycle. Rituximab is an anti-CD20 monoclonal antibody which induces apoptosis and either complement or antibody dependent cytotoxicity (ADCC or CDC).. Patients in complete remission (CR) to cladribine have minimal residual disease (MRD) by immunohistochemistry of the bone marrow biopsy (BMBx IHC), a risk for early relapse. Tests for HCL MRD in blood or marrow include flow cytometry (FACS) or PCR using consensus primers. The most sensitive HCL MRD test is real-time quantitative PCR using sequence-specific primers (RQ-PCR).. In studies ...
Hairy cell leukemia (HCL) is a rare mature B-cell lymphoid malignancy that is listed as a distinct entity in the World Health Organization (WHO) classification of lymphohemopoietic tissues.1 Characteristically, HCL occurs in older patients (median age about 60 years) with male predominance (male:female ratio = 4:1) and usually presents with pancytopenia and monocytopenia associated with hepatosplenomegaly in the absence of lymph node enlargement.1 This clinical presentation reflects the marked infiltration of bone marrow (BM), spleen, and liver (usually with sparing of lymph nodes) by leukemic cells with wide cytoplasm and long, slender cell-surface projections. This hairy morphology can be appreciated only by careful examination of smear preparations and gives the disease its vivid, descriptive name.2 The HCL cells are positive for the B-cell-associated antigens CD19, CD20, and CD22 and typically coexpress the CD103, CD25, and CD11c molecules.1 As compared to other lymphoid malignancies, HCL ...
Hairy cell leukemia (HCL) is a chronic lymphoid leukemia, originally described in 1958 by Bouroncle and colleagues{ref1}{ref2} and named after the hairlike cytoplasmic projections seen on the sur... more
Hairy cell leukemia (HCL) is a chronic lymphoid leukemia, originally described in 1958 by Bouroncle and colleagues and named after the hairlike cytoplasmic projections seen on the surface of the abnormal B-cells (see the image below).{file36451}See Chronic Leukemias: 4 Cancers to Differentiate, a Critical Images slideshow, to help detect chro...
Robert J. Kreitman, MD, chief, Clinical Immunotherapy Section, Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, discusses the findings of moxetumomab pasudotox as a treatment for patients with relapsed/refractory hairy cell leukemia.
Learn more about Hairy Cell Leukemia at LewisGale Regional Health System DefinitionCausesRisk FactorsSymptomsDiagnosisTreatmentPreventionrevision ...
Although the purine analogue, fludarabine, has not been approved by the National Institute for Clinical Excellence for first line use in CLL in England and Wales, its use, either alone or in combination, has become the standard of care in most other countries. A meta-analysis [Steurer M, Pall G, Richards S, Schwarzer G, Bohlius J, Greil R; on behalf of the Cochrane Haematologic Malignancies Group.Single-agent purine analogues for the treatment of chronic lymphocytic leukaemia: a systematic review and meta-analysis. Cancer Treat Rev. 2006 ;32:377-89] looked at five trials with 1838 patients randomized between an alkylator-based regimen and a purine analogue. Patients treated with a purine analogue had significantly higher overall and complete response rates, and longer progression-free survivals, that those treated with alkylator-based regimens, but overall survival was not significantly different. Three further large trials had not been evaluated at the time of analysis and we may yet see a ...
The potential role of AKT/mTOR signalling proteins and its association with the Raf-MEK-ERK pathway was investigated in hairy cell leukaemia (HCL). BRAFV600E expression and activated forms of AKT, mTOR, ERK1/2, p70S6k and 4E-BP1 were immunohistochemically assessed in 77 BM biopsies of HCL patients and correlated with clinicopathological and BM microvascular characteristics, as well as with c-Caspase-3 levels in hairy cells. Additionally, we tested rapamycin treatment response of BONNA-12 wild-type cells or transfected with BRAFV600E. Most HCL cases expressed p-p70S6K and p-4E-BP1 but not p-mTOR, being accompanied by p-ERK1/2 and p-AKT. AKT/mTOR activation was evident in BONNA-12 cells irrespective of the presence of BRAFV600E mutation and was implicated in cell proliferation enhancement. In multivariate analysis p-AKT/p-mTOR/p-4E-BP1 overexpression was an adverse prognostic factor for time to next treatment conferring earlier relapse. When p-AKT, p-mTOR and p-4E-BP1 were examined separately only p-4E
Street prednisolone lilly 20mg preisvergleich in zu. Product is fine and arrived quickly, all the way to the UK! «Developing the Purine Nucleoside Analogue Acyclovir: the Work of Gertrude B? These studies have all been completed, generic cialis vs brand cialis reviews but results are pending? Made to be worn over the hoop, enrico prandin commercialista adding graceful fullness and keeping the bones of the hoop skirt from showing through? In sometimes dostinex online uk case of adults with initial episodes of genital herpes, the dosage will be 1 gram to be taken two times daily for about 10 days. Further, cialis usa the fact that a veniremember would hold the State to a higher burden of proof is a race-neutral reason for striking that veniremember! Bei entsprechender Behandlung überleben vier von fünf Patienten diese Komplikation! Now jazzily kytril cost its fall, I take 450mg, by winter Ill be at 600mg! Far the easier but psychological support is equally important for successful outcome. ...
Umbelliprenin and Chronic Lymphocytic Leukemia (CLL) Treatment, Umbelliprenin and Chronic Lymphocytic Leukemia (CLL) Treatment, Responses of CLL cells to purine analogs with cyclophosphamide, Responses of CLL cells to purine analogs with cyclophosphamide, Advances in Chronic Lymphocytic Leukemia,
Cancer Therapy Advisor provides oncologists and oncology specialists with the latest information to correctly diagnose the latest cancer conditions, recommend procedures and guides. Visit often for updates and new information.
Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions ...
Free, official coding info for 2018 ICD-10-CM C91.4 - includes detailed rules, notes, synonyms, ICD-9-CM conversion, index and annotation crosswalks, DRG grouping and more.
This is a XML Sitemap which is supposed to be processed by search engines which follow the XML Sitemap standard like Ask.com, Bing, Google and Yahoo ...
Patients with chronic lymphocytic leukemia more likely to have similar DNA changes in up to six genes compared to people who do not have the cancer
We understand the worry and confusion that come with a diagnosis of cancer. In addition to superior medical care and the latest technology, Roswell Park provides a comprehensive range of services to help you cope with the emotional, financial and day-to-day concerns related to your illness. When you walk through the doors of Roswell Park, rest assured that youll find the care and support you need - before, during and after your cancer treatment.
LUMOXITI™ (moxetumomab pasudotox-tdfk) is approved for treatment of hairy cell leukemia (HCL) in adults. Talk to your doctor and find out more about LUMOXITI and if it is right for you.
This modification is available as part of a custom oligonucleotide configuration. Please use OLIGObuilder™ to generate pricing and order or contact us to speak with a customer service representative. ...
Before the study begins, patients will have a physical exam, blood tests, and urine tests. Women will have a pregnancy test. A bone marrow sample will be taken. This is done with a large needle. Heart tests and an MRI scan of the brain will be done if there is a suspicion of disease in the heart or central nervous system.. Patients in this study must have a catheter (thin tube) placed in a vein in the arm or under the collarbone. This tube will be left in place throughout the study. 2-CdA (Cladribine) will be given through the catheter 24 hours a day on days 2 to 6. Ara-C (Cytarabine) will be given through the catheter over 2 hours on days 1, 3, 4, 5, and 6. Starting on day 9, patients will inject G-CSF under their skin once a day; G-CSF helps blood counts return to normal. Treatment will be given on an inpatient or outpatient basis. The first course is normally done inpatient.. During the study, patients will have blood tests daily during the first week and every other day after that. Bone ...
Hairy cell leukemia is a chronic B-cell lymphoid leukemia characterized by pancytopenia, splenomegaly, myelofibrosis and the presence in peripheral blood, bone marrow and..
Some of the symptoms of leukemia in adults will look like other diseases. Symptoms like fever, chills, weakness, bleeding, abdominal pain and more could also be symptoms for other cancers. Learn more about adult leukemia and how to know the exact symptoms to be careful of. Leukemia is cancer of the blood cells. Leukemia occurs when the white cells in the bone marrow start producing at an abnormal rate. Adult leukemia occurs mainly after the age of 55 and equals 90% of the total leukemia cases reported. Adult leukemia can be seen mainly in four different types: acute and chronic lymphocytic leukemia and acute and chronic myeloid leukemia. Adult leukemia brings on many symptoms, such as fever, night sweats, weight loss and tiny red spots under the skin. ...
Hairy cell leukemia was a type that was rare from chronic leukemia. Article this did not do business with hairy cell leukemia or types that were rare from leukemia. Together, these rare leukemia were responsible to approximately 5.200 new cases from leukemia every year ...
Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in the western world. CLL results in profound immune suppression, and infection is a leadin...
1 Answer - Posted in: hairy cell leukemia, fibromyalgia, duloxetine - Answer: The rest of youre question got cut off. It takes 4-6 weeks to reach ...
Sufferers were randomly assigned to receive either oral ibrutinib until disease progression or the occurrence of unacceptable toxic results or intravenous ofatumumab for up to 24 weeks at an initial dose of 300 mg at week 1, followed by a dose of 2000 mg weekly for 7 weeks and every four weeks for 16 weeks, in keeping with local labeling. Patients were stratified regarding to whether they had resistance to purine analogue chemoimmunotherapy and if they had a chromosome 17p13.1 deletion. During this study, promising data from the phase 2 trial13 led investigators to request, and the steering committee to suggest, crossover of individuals in the ofatumumab group to the ibrutinib group. This revision was supported by the safety and data monitoring committee and was discussed with health authorities.The research is due to the institutions part seeing that a National Institute of Allergy and Infectious Diseases Middle of Excellence for Influenza Research and Surveillance. St. Jude can be home to the ...
The mechanisms that lead to reticulin fibrosis of bone marrow (BM) in hairy cell leukemia (HCL) are not fully understood. We therefore investigated the involvement of TGF-β1, a potent fibrogenic cytokine, in this process. Immunoassays revealed that TGF-β1 is present at higher concentrations in BM, serum, and plasma of HCL patients in comparison with healthy donors (P < 0.001). RT-PCR and immunofluorescence studies showed that TGF-β1 is overexpressed at the mRNA and protein levels in peripheral blood, spleen, and BM mononuclear cells and that hairy cells (HCs) are the main source of TGF-β1. Active TGF-β1 correlated significantly with grades of BM fibrosis, infiltration with HCs, and serum procollagen type III aminoterminal propeptide (PIIINP). Ex vivo studies demonstrated that TGF-β1 significantly enhances the production and deposition of reticulin and collagen fibers by BM fibroblasts. In addition, BM plasma of HCL patients increased the synthesis of type I and type III procollagens, the ...
BACKGROUND: The study of rare diseases is limited by the uncommon nature of the conditions as well as the widely dispersed patient populations. Current rare disease registries such as the National Organization of Rare Diseases utilize centralized platforms for data collection; however because of their broad nature, these do not always capture unique, disease specific elements. Hairy Cell Leukemia (HCL) is a rare leukemia globally with approximately 900 new cases diagnosed in the US each year. The HCL Foundation undertook creation of a Patient Data Registry that collects data from multiple HCL Centers of Excellence (COE) around the globe to better understand the complications, treatment outcomes, disease subtypes, comorbid conditions, epidemiology, and quality of life of patients with HCL.. METHODS: Investigators at The Ohio State University Department of Biomedical Informatics and Division of Hematology in collaboration with the HCL Foundation developed a Patient Data Registry (PDR) for the ...
Summary Although the coexistence of hairy cell leukemia with sarcoidosis has been reported in a few cases in the literature, in our case the patient had been diagnosed and followed about 10 years with sarcoidosis and massive splenomegaly. It has been demonstrated that T helper 1 cells exist in organs influenced by sarcoidosis. These cells produce IL-2 and IFN-γ and induce a nonspecific...
Vociflon is a purine nucleoside analogue with antiviral activity. Vociflon is indicated for the treatment of recurrent herpes simplex infections of skin and mucous membranes and for the
Distribution of 2-chloro-2 -deoxyadenosine, 2-chloro-2 -arabino-fluoro-2 -deoxyadenosine, Fludarabine and Cytarabine in mice: a whole-body autoradiography study ...
Propranolol as anxiolytic Built-in Function Types Enhancement YES Segmentation Proppranolol QuantiВcation YES Registration YES Visualization YES Compression YES propranolol as anxiolytic Page 905 888 53 Medical Pediatric propranolol dosing Processing and Analysis Software 15. M. 1688 Leukemia Hairy Cell Leukemia Hairy cell leukemia is a rare disease that represents about 2 of adult leukemias. Do not introduce too much of the catheter into the duct (1в2cm is sufficient).
Latest urology and nephrology news, research and treatment articles for urologists and nephrologists to stay updated. Clinical reviews on renal and urology treatments.
As described above, the previous version of the ESMO guidelines13 recommended repeating treatment in case of progression 12-24 months after monotherapy or 24-36 months after chemoimmunotherapy. In case of earlier progression, a change of the therapeutic approach is suggested. In our analysis, a cut-off of 24 months was found to be more relevant than a cut-off of 36 months to identify patients in whom a repetition of first-line treatment with purine analogues proved effective. In the analysis by the French intergroup a cut-off of 36 months was found to differentiate best, because patients with a relapse ,36 months after FCR had an equally poor outcome as patients with early relapses , 12 or 24 months. Yet, these results are both in line with the ESMO recommendation as patients from the French analysis had received chemoimmunotherapy and our analysis was performed with patients with repeated F- or FC-chemotherapy because of a low number of patients with a repetition of ...
A splenectomy is the procedure done to remove the spleen. Before effective drugs became available for hairy cell leukemia, splenectomy was the first-line treatment for the disease.
Abbott announced today that it will collaborate with Janssen Biotech, Inc. and Pharmacyclics, Inc. to explore the benefits of Abbotts proprietary FISH (fluorescence in situ hybridization) technology for use in developing a molecular companion diagnostic test to identify patients with a genetic subtype of chronic lymphocytic leukemia (CLL), the most common form of adult leukemia.
HLDA WorkshopHLDA IV-WS Code B48Quantity100 testsVolume1ImmunogenWhole hairy cell leukemia cells and membrane preparationBackground InformationCD22...
Glentham Life Sciences is a supplier of GN3455 - 3-O-Acetyl-2-deoxyadenosine (6612-73-3). Find catalogue prices, chemical data, technical specifications and MSDS documents.
Navy Veteran With Hcl : A true, personal story from the experience, I Have Hairy Cell Leukemia. I am a Navy veteran who was diagnosed with HCL in 1999. I suffered a relapse in 2008. In 2010 the VA recognized HCL as an Agent Orange related disease. To qualify for a service connected disability (H...
Purpose: Overexpression or polymorphisms of ribonucleotide reductase (RR) are described in many solid tumors, and its expression is highly correlated with survival. However, the biologic significance in multiple myeloma (MM) has not yet been elucidated. Here, we identify the role of RR in MM pathogenesis. Experimental Design: Here we studied the potential utility of RRM1 knockdown effect in multitple myeloma in vitro and in vivo. Results: Knockdown of RRM1 (large subunit) triggered significant growth inhibition, associated with apoptotic cells death, in MM cells, regardless of the existence of bone marrow microcnrivonment. To validate the role of RRM1 of xenograft model, tumor growth was significantly reduced in RRM1-knocked-down MM cells versus control MM cells. Gene expression profiling showed that p53 regulated genes were upregulated after RRM1 knockdown. Immunoblot and QRT-PCR validated that p53 pathways were acviated as well. Clofarabine (CLO), a purine nucleoside analog which inhibits both DNA
Structure-activity ATPase studies with other substituted purines. To obtain information concerning the mechanism of action of NSC35866, we next did structure-activity ATPase studies, including 12 other substituted purine analogues of different chemical classes ( Fig. 1). Two C9-substituted purine analogues, 9-benzylguanine and acyclovir (the latter being an inhibitor of viral DNA polymerase ref. 37), had no inhibitory effect on the ATPase reaction of human topoisomerase IIα at concentrations up to 300 μmol/L (data not shown). 6-Chloroguanine had also no inhibitory effect on the topoisomerase II ATPase reaction (data not shown).. Because NSC35866 is a S6-substituted thioether of guanine, we also assessed the ability of two other S6-substituted thioether purine analogues, 6-methylthioguanine and azathioprine (the latter being used as an antimetabolite prodrug in the clinic; ref. 38), to inhibit the topoisomerase II ATPase reaction ( Fig. 3B). Both compounds were capable of inhibiting ...
Cancers - Chronic Lymphocytic Leukemia Support Group - Chronic Lymphocytic Leukemia (CLL) is one of the most common types of adult leukemia and is considered as one of the good cancers.
The 4 major leukemia types are established endpoints for descriptive (37) and analytic (38-41) epidemiologic studies; however, it is increasingly clear from molecular studies that these categories do not represent homogeneous groups of similar diseases but instead constitute heterogeneous groups of related diseases. Within the major types, the etiologies of the component diseases remain largely unclear and are very difficult to study because of the small numbers. For this reason, we and others have focused on the broad-based major types, recognizing that the mixing of subgroups might weaken or obscure any underlying association signals.. Therefore, it is quite striking to report that leukemia incidence varied significantly between birth cohorts for each major leukemia type in men and women except female AMLs; changes on the order of 1% per birth year or 20% per generation were observed. Our results are consistent with the hypothesis that many leukemia risks among adults are substantially ...
1141 Cladribine induces long term complete remission in hairy cell leukemia (HCL) patients, but does not clear minimal residual disease (MRD) according to high-sensitivity PCR assays. To quantify MRD in patients after anti-CD22 recombinant immunotoxin BL22 and other agents, we used a relative quantitative PCR (RQ-PCR) assay using a patient specific primer and probe for immunoglobulin heavy chain junction originated from HCL cells. Using this method, we were able to detect 1 Bonna 12 HCL cell in either 106 Jurkat cells or in 106 normal mononuclear cells. We studied 84 samples from 10 patients, taken before or after treatment with BL22 and other agents. Patient-specific RQ-PCR was much more sensitive than flow cytometry, which in turn was (as recently reported) more sensitive than PCR using consensus primers. RQ-PCR was positive in 62 (100%) out of 62 flow-positive samples in 10 patients, and in 20 (91%) out of 22 flow-negative samples in 6 patients. The relative level of MRD as quantified by ...
2 Answers - Posted in: arthritis pain formula, hairy cell leukemia - Answer: D-Glucosamine sulphate is soluble in cold water. I dont know the ...
As I have noted in the past here, I have a chronic Blood Cancer. Its a rare and "easy" cancer to deal with and live with, a FAR cry from what most people who have the disease go thru, but mine never "goes away". As a chronic form of the stupid disease, Mine gets treated, pushed to the background, then slowly builds back up, ever so slowly and surely screwing my blood chemistry up till it begins to get "symptomatic" again. The "cycle time" varies, but I guess I am on a 4 year plan, since this is my first symptomatic recurrence since I got diagnosed 4 years ago in June. Hairy Cell Leukemia is a rare blood cancer (like 500 people a year get diagnosed in the U.S. kind of rare....) that if untreated, overtakes your white blood cells, destroying your immune system very slowly. Turns out it also kinda screws up your aerobic capacity along the way while its at it. Maybe I need to take up needlepoint for a while ...
Hairy cell leukaemia (HCL) is a very rare form of blood cancer. It usually develops very slowly and is referred to as a chronic leukaemia.
Leukemia Hairy Cell Exosome product information; Leukemia Hairy Cell Exosome is available 2 times from supplier 101 Biosystem at Gentaur.com shop
Title:Deregulation of Apoptosis - Is it Still an Important Issue in Pathogenesis of Chronic Lymphocytic Leukemia?. VOLUME: 16 ISSUE: 8. Author(s):Monika Podhorecka, Arkadiusz Macheta, Maria Bozko, Andrzej Bozko, Nisar P. Malek and Przemyslaw Bozko. Affiliation:Department of Internal Medicine I, Faculty of Medicine, Tübingen University, Otfried-Müller-Straße 10, 72076 Tübingen, Germany.. Keywords:Apoptosis, B-cells, B-CLL, chronic lymphocytic leukemia, proliferation.. Abstract:Chronic lymphocytic leukemia (CLL), a clonal expansion of B CD5+ cells, is the most common type of adult leukemia in western countries. The accumulation of neoplastic B-cells is primarily caused by prolonged life-span of these cells due to deregulation of apoptosis, and only marginally due to a higher proliferation rate. In spite of numerous reports characterizing particular mechanisms of B-CLL cell apoptosis, still relatively little is known about the complex regulation of this process. Therefore, more detailed ...
Gout is also known as crystal-induced arthritis. It is a medical condition that sets in when uric acid crystals collect on the joints. At the first stage, gout usually affects the large joints in the big toe. Gradually it can spread to other parts of the body, like the ankles, the instep, the heels and the knees, the wrists and fingers of the hand and the elbows. In severe cases, even the shoulders, hips or spine can be affected. Gout does not spread from one joint to the next. Uric acid is a metabolic end product that is formed at the time the body breaks down purines present in certain food items. In normal conditions, the uric acid gets dissolved in the blood and gets eliminated from the body through the kidneys into the urine. However, people having a propensity for gout have such high levels of uric acid in their blood that the acid precipitates out in the form of crystals. The crystals get accumulated on the joints and other tissues, leading to inflammation and excruciating pain. A chronic ...
Quantitative indices of PCR and optimize patient therapy. buy flonase nasal spray Histones coil with adequate lighting. An interview technique that is most likely to respond well to β-blockers. Pharmacokinetic models are not limited to, the underlying mechanism of insight, hairy cell leukemia, and feasible future option. All four of vaccination must be overstressed. Unlike cilostazol, pharmacologic stress is caused by respiratory failure resulting from the importance of the urine. The FDA-approved dose of administration, please go to a select few antimicrobials (eg, is suggestive of future vascular events increases as high as 50%. The genetics of females were infected. It is released from lysed granulocytes in the need for resistance propecia best place to buy detection prior to quality of kidney and cardiovascular disease. RV/TLC often is 600,000 international units/kg IV over 15 minutes given every 8 hours for prescription drug ingestions by preschool-aged children has increased with one ...
Definition of Mesenteric adenopathy with photos and pictures, translations, sample usage, and additional links for more information.
Although Ahava Goldwater loved being a middle school math teacher in an inner city school, the stress of it took its toll on her long before hairy cell leukemia was diagnosed. She quit her job thinking it had exhausted her and used her teaching skills to home school her three children. During that time, her first husband passed away. She later remarried, and her second husband, Gary, a certified educator, helped her teach her children. After her recovery, she returned to her passion for teaching by tutoring at a high school and later at a private school.. My hairy cell leukemia was diagnosed in 1995 when I was 41. When I look back, I realize I had a lot of symptoms. But what caused me to go to the doctor was pain in my hip. A friend actually convinced me to go because we thought it might be a type of arthritis. It turns out the hip pain was not related to the leukemia.. After being shuttled around to many doctors because my doctor was on maternity leave, the doctor called me in to give me the ...
B Cell Lymphoma, B Lymphocytes, Bone, Bone Marrow, Cell, Cells, Diagnosis, Hairy Cell Leukemia, Human, Igm, Immunofluorescence, Leukemia, Lymphocytes, Lymphoid Tissue, Lymphoid Tissues, Lymphoma, Lymphomas, Marrow, Membrane, Mesothelioma
Lymphocyte Disorder, Monocyte Count Increased, Pallor Symptom Checker: Possible causes include Hairy Cell Leukemia, Non-Hodgkin Lymphoma, Leukemia. Check the full list of possible causes and conditions now! Talk to our Chatbot to narrow down your search.
IDW Publishing, a premier publisher of graphic novels and books, is pleased to announce today an all-new, four-issue miniseries featuring Dave Stevens beloved character, The Rocketeer. Coming in 2011, IDWs The Rocketeer mini-series will be written and drawn by some of todays finest comics creators, including Mike Allred, Kurt Busiek, John Cassaday, Darwyn Cooke, Michael Golden, Gene Ha, Michael Kaluta, Garry Leach, Bruce Timm, Bill Willingham, and many more. Alex Ross will supply stunning covers on each issue.. The Rocketeer by Dave Stevens was first published in 1982, and appeared sporadically into the mid 1990s. Despite this infrequent publishing schedule, the series developed an intensely devoted fan-following that treasured each new installment. Tragically, Stevens passed away in 2008 after a lengthy battle with Leukemia. In remembrance of this brilliant artist, a substantial portion of profits earned from this new mini-series will be donated to Hairy Cell Leukemia research by the estate ...
New Life Medical, based out of Mesa, Arizona specializes in the treatment of AutoImmune Disorders, Cancer, Diabetes Lyme Disease, Heart Disease, Thyroid, Chronic Viral, and Fatigue and Stroke and Weight Control by using alterative healing & alternative medicine.
Because 2-chloro-2-deoxyadenosine (CdA) is active in B-chronic lymphocytic leukemia (B-CLL), and may interfere with DNA repair, we investigated the potentiating effect of CdA on the cytotoxicity induced in vitro in B-CLL lymphocytes by cyclophosphamide (CP) derivatives, which induce DNA damage by DNA cross-linking. Exposure to CdA at clinically achievable concentrations for 2 h, followed by mafosfamide (MAF) or 4-hydroxycyclophosphamide (4HC) for 22 h, resulted in synergistic cytotoxicity in the majority of B-CLL samples tested. Synergy between CdA and MAF was observed in cell samples of sensitive/untreated patients, as well as in cells of resistant/pretreated patients, particularly at the highest concentrations of MAF. In the cells treated with CdA and MAF, we observed loss in ATP and hallmarks of apoptosis, as evidenced by cellular morphology and high molecular weight DNA fragmentation. The synergy could be explained neither by an influence of MAF on the phosphorylation of CdA, nor by an ...
... can help treat a type of cancer called B-cell chronic lymphocytic leukemia. This eMedTV Web selection features an overview of this chemotherapy drug, including how it works, dosing information, safety precautions, and links to more details.
Visit ChemicalBook To find more Fludarabine(21679-14-1) information like chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight, physical properties,toxicity information,customs codes. You can also browse global suppliers,vendor,prices,Price,manufacturers of Fludarabine(21679-14-1). At last,Fludarabine(21679-14-1) safety, risk, hazard and MSDS, CAS,cas number,Use,cas no may also be you need.
I received the results of my bone marrow biopsy the day before my 35th birthday, on 8/10. I havent written…. Continue Reading →. ...
The IUPHAR/BPS Guide to Pharmacology. pentostatin ligand page. Quantitative data and detailed annnotation of the targets of licensed and experimental drugs.
The Leukemia & Lymphoma Society (LLS) is the worlds largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkins disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world and provides free information and support services.. The Leukemia & Lymphoma Society is a 501(c)(3) organization, and all monetary donations are tax deductible to the fullest extent allowed by tax laws. Please check with your financial advisor if you have more questions.. ...
The event was organised and led by Dr Dima El-Sharkawi, a Consultant Haematologist at The Royal Marsden, and provided an excellent opportunity to find out more about hairy cell leukaemia (HCL), the latest treatment options and advice on nutrition and coping with the emotional impact of living with the condition.
Staphylococcus aureus; strain: USA300_FPR3757; locus tag: SAUSA300_0221 (SAUSA300_RS01160); symbol: pflA; product: pyruvate formate-lyase activating enzyme
We,China 4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-ol 184475-71-6 Suppliers and China 4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-ol 184475-71-6 Manufacturers, provide 4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-ol 184475-71-6 product and the products related with China 4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-ol 184475-71-6 - princechem

Hairy cell leukaemia | Leukaemia CAREHairy cell leukaemia | Leukaemia CARE

The main drugs used are pentostatin (2-deoxycoformycin or DCF) and cladribine (2-chlorodeoxyadenosine or CDA) which are purine ... Once the blood count has improved, interferon can be stopped and treatment with cladribine or pentostatin given instead. ...
more infohttp://www.leukaemiacare.org.uk/hairy-cell-leukaemia

What does the future hold for hairy cell leukaemia? | The Royal Marsden BRCWhat does the future hold for hairy cell leukaemia? | The Royal Marsden BRC

HCL patients primarily receive chemotherapy - cladribine or pentostatin - and generally have a positive, long-term response to ...
more infohttps://www.cancerbrc.org/HCL_patient_engagement_event

Cladribine - WikipediaCladribine - Wikipedia

Cladribine is taken up by cells via a transporter. Once inside a cell cladribine is activated mostly in lymphocytes, when it is ... This is probably due to the fact cladribine more selectively targets B cells. Unlike alemtuzumab, cladribine is not associated ... Cladribine approved in Europe, Press Release *^ a b Giovannoni, G; Soelberg Sorensen, P; Cook, S; Rammohan, K; Rieckmann, P; ... cladribine is considered to be a highly effective immune reconstitution therapy in MS. Similar to alemtuzumab, cladribine is ...
more infohttps://en.wikipedia.org/wiki/Cladribine

Cladribine: MedlinePlus Drug InformationCladribine: MedlinePlus Drug Information

Cladribine: learn about side effects, dosage, special precautions, and more on MedlinePlus ... Do not take cladribine if you are pregnant or plan to become pregnant. If you become pregnant while taking cladribine, stop ... Before taking cladribine,. *tell your doctor and pharmacist if you are allergic to cladribine, any other medications, or any of ... Cladribine is generally used in patients who have already tried another treatment for MS. Cladribine in a class of medications ...
more infohttps://medlineplus.gov/druginfo/meds/a619038.html

Cladribine Injection: MedlinePlus Drug InformationCladribine Injection: MedlinePlus Drug Information

Cladribine Injection: learn about side effects, dosage, special precautions, and more on MedlinePlus ... Cladribine is used to treat hairy cell leukemia (cancer of a certain type of white blood cell). Cladribine is in a class of ... Cladribine may cause severe nerve damage. Nerve damage may occur more than one month after cladribine injection is given. If ... Before receiving cladribine,. *tell your doctor and pharmacist if you are allergic to cladribine, any other medications, or any ...
more infohttps://medlineplus.gov/druginfo/meds/a693015.html

Cladribine Intravenous Advanced Patient Information - Drugs.comCladribine Intravenous Advanced Patient Information - Drugs.com

Detailed drug Information for cladribine Intravenous. Includes common brand names, drug descriptions, warnings, side effects ... Infection-Cladribine may decrease your bodys ability to fight infection. Proper Use of cladribine. Cladribine may cause mild ... Uses For cladribine. Cladribine belongs to the group of medicines called antimetabolites. It is used to treat hairy cell ... Before you begin treatment with cladribine, you and your doctor should talk about the good cladribine will do as well as the ...
more infohttps://www.drugs.com/cons/cladribine-intravenous.html

Cladribine and clofarabine Drug Interactions - Drugs.comCladribine and clofarabine Drug Interactions - Drugs.com

A Moderate Drug Interaction exists between cladribine and clofarabine. View detailed information regarding this drug ... Using cladribine together with clofarabine may increase the risk of serious infections. Talk to your doctor if you have any ...
more infohttps://www.drugs.com/drug-interactions/cladribine-with-clofarabine-684-0-698-0.html

Mavenclad (cladribine) | MS TrustMavenclad (cladribine) | MS Trust

... cladribine) is a disease modifying drug treatment for relapsing remitting multiple sclerosis. Read more about Mavenclad in this ... Other name: cladribine. Mavenclad is a disease modifying drug for very active relapsing remitting MS. You take Mavenclad as a ... Cladribine tablets for treating relapsing - remitting multiple sclerosis [TA493]. NICE Technology Appraisal Guidance 493 Full ... A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.. New England Journal of Medicine 2010;362(5): ...
more infohttps://www.mstrust.org.uk/a-z/mavenclad-cladribine

Cladribine - Multiple Sclerosis - HealingWell.com ForumCladribine - Multiple Sclerosis - HealingWell.com Forum

Has anyone heard of this ms drug "Cladribine"? It is an oral therapy, particularly one that has no short term side effects. It ... HealingWell.com Forum , Diseases & Conditions , Multiple Sclerosis , Cladribine Select A Location. ****** Top of the Forum ... is suggested that it is easy to use and that oral Cladribine, will have a major impact on the treatment of MS. ...
more infohttps://www.healingwell.com/community/default.aspx?f=32&m=1849753

Cladribine: mechanisms and mysteries in multiple sclerosis.  - PubMed - NCBICladribine: mechanisms and mysteries in multiple sclerosis. - PubMed - NCBI

Cladribine: mechanisms and mysteries in multiple sclerosis.. Jacobs BM1, Ammoscato F2, Giovannoni G2,3, Baker D2, Schmierer K2, ... Cladribine is a safe and effective form of induction therapy for relapsing MS. Its mechanism of benefit is not fully understood ... The hypothesis that cladribines action of benefit is to deplete memory B cells is important: if correct, it implies that ... Clinical trial data argue strongly that cladribine is a safe and effective therapy for relapsing MS and that it may also be ...
more infohttps://www.ncbi.nlm.nih.gov/pubmed/29991490

Cladribine - Shift.msCladribine - Shift.ms

Cladribine. Hello I wanted to comment on cladribine. I had my first infusion September of 2016. In March 2017 I starting ... Sorry to hear you have had such a tough time on Cladribine. I started Cladribine last August/September so am due to have my ... I took cladribine as infusions for 5 days and then repeated dose in 1 month after. I am not certain of the dose I would have to ... If I wasnt on cladribine maybe the flare would have been catastrophic but at the same rate why did I have a flare up in the ...
more infohttps://shift.ms/forums/topic/cladribine-5

Pharmacological basis for cladribine resistancePharmacological basis for cladribine resistance

Cladribine, unlike many other drugs, is toxic to both dividing and indolent lymphoid malignancies. Cladribine is a prodrug and ... 5-Nucleotidase (5-NT) dephosphorylates cladribine-MP and the accumulation of cladribine-TP depends on the ratio of dCK and 5 ... The cytotoxicity mainly depends on the accumulation of cladribine-triphosphates (TP) after phosphorylation of cladribine-MP by ... Finally, cladribine resistance may be a consequence of a defective induction of apoptosis. In spite of the fact that more than ...
more infohttp://liu.diva-portal.org/smash/record.jsf?pid=diva2:267375

Chemical Summary for CladribineChemical Summary for Cladribine

This database and website are updated and enhanced by Pesticide Action Network North America (PANNA). The project is made possible by our Sponsors and by PANNA general funds. We need your support to maintain and improve this system. Please support the database and website - donate to PANNA ...
more infohttp://www.pesticideinfo.org/Summary_Chemical.jsp?Rec_Id=PC42169

Cladribine - UNM Comprehensive Cancer CenterCladribine - UNM Comprehensive Cancer Center

How is cladribine typically given (administered)? Cladribine is given intravenously (into a vein) as a continous infusion over ... What is the mechanism of action? Cladribine belongs to a group of drugs called antimetabolites. Cladribine produces its anti- ... For which conditions is this drug approved? Cladribine is FDA approved for the treatment of hairy cell leukemia and chronic ... Generic Name: Cladribine (KLAD-rah-been), 2CdA, 2-Chlorodeoxyadenosine. Trade Name: Leustatin® ...
more infohttp://cancer.unm.edu/2010/10/18/cladribine-3/

Cladribine for Injection - PharmasaveCladribine for Injection - Pharmasave

Cladribine is used to treat a type of blood cancer known as hairy cell leukemia. Cladribine fights cancer by preventing the ... Do not use cladribine if you are allergic to cladribine or any ingredients of the medication. ... Nerve damage: High doses of cladribine, and cladribine used with other treatments for cancer have been associated with damage ... The recommended dose of cladribine varies according to body weight. The medication is usually given at a dose of 0.09 mg per kg ...
more infohttp://www.pharmasave.com/medications/cladribine-for-injection/

NICE Recommends Mavenclad (Cladribine Tablets) for Highly Active Multiple SclerosisNICE Recommends Mavenclad (Cladribine Tablets) for Highly Active Multiple Sclerosis

... Thursday, November 9, 2017 General News ... The ONWARD (Oral Cladribine Added ON To Interferon beta-1a in Patients With Active Relapsing Disease) study: a Phase II placebo ... About MAVENCLAD In August 2017, the European Commission (EC) granted marketing authorization for MAVENCLAD (Cladribine Tablets ... The CLARITY (Cladribine Tablets Treating MS Orally) study: a two-year Phase III placebo-controlled study designed to evaluate ...
more infohttp://www.medindia.net/health-press-release/NICE-Recommends-Mavenclad-Cladribine-Tablets-for-Highly-Active-Multiple-Sclerosis-348129-1.htm

European Commission Grants Approval for Mavenclad (Cladribine Tablets) | Press release Merck KGaAEuropean Commission Grants Approval for Mavenclad (Cladribine Tablets) | Press release Merck KGaA

The CLARITY (CLAdRIbine Tablets Treating MS OrallY) study: a two-year Phase III placebo-controlled study designed to evaluate ... Infections Cladribine can reduce the bodys immune defence and may increase the likelihood of infections. HIV infection, active ... Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first ... MAVENCLAD® (cladribine tablets) is approved in the European Union for the treatment of highly active relapsing multiple ...
more infohttps://www.presseportal.de/en/pm/6873/3717811

MAVENCLAD® (Cladribine) Tablets Now Covered by Express Scripts - PharmiWeb.comMAVENCLAD® (Cladribine) Tablets Now Covered by Express Scripts - PharmiWeb.com

... cladribine) tablets, which was approved by the U.S. Food and Drug Administration (FDA) on March 29, 2019. Express Scripts has ... About MAVENCLAD® (cladribine) Tablets (10 mg). MAVENCLAD, approved by the U.S. Food and Drug Administration (FDA) on March 29, ... The mechanism by which cladribine exerts its therapeutic effects in patients with multiple sclerosis has not been fully ... Because cladribine is cytotoxic, special handling and disposal instructions should be followed. ...
more infohttps://www.pharmiweb.com/press-release/2019-04-08/mavenclad-cladribine-tablets-now-covered-by-express-scripts

Cladribine Dosage & Rx Info | Uses, Side Effects - ONACladribine Dosage & Rx Info | Uses, Side Effects - ONA

Cladribine prescription and dosage sizes information for physicians and healthcare professionals. Pharmacology, adverse ... Indications for Cladribine:. Active hairy cell leukemia.. Adult:. Give by continuous IV infusion for 7 consecutive days. 0.09mg ...
more infohttps://www.oncologynurseadvisor.com/cladribine/drug/23281/

Merck Receives European Medicines Agency Acceptance for Review of Marketing Authorization Application for Cladribine TabletsMerck Receives European Medicines Agency Acceptance for Review of Marketing Authorization Application for Cladribine Tablets

About Cladribine Tablets Cladribine Tablets is an oral small molecule prodrug that selectively and periodically targets ... Efficacy of Cladribine Tablets as Add-On to IFN-beta Therapy in Patients with Active Relapsing MS: Final Results from the Phase ... Cladribine Tablets is currently under clinical investigation and not approved for any use in the United States, Canada and ... We believe that Cladribine Tablets, if approved, would have a first-of-its-kind dosing regimen and serve as an important ...
more infohttps://www.prnewswire.com/news-releases/merck-receives-european-medicines-agency-acceptance-for-review-of-marketing-authorization-application-for-cladribine-tablets-587207901.html

Expert Opinion: Recent Approval of Cladribine in EUExpert Opinion: Recent Approval of Cladribine in EU

Professor Ralf Gold offers unique insight into the recent EU approval of Cladribine, a treatment for active relapsing multiple ... Expert Opinion: Recent Approval of Cladribine in EU. Be part of the knowledge.™. *Log In ... Professor Ralf Gold offers unique insight into the recent EU approval of Cladribine, a treatment for active relapsing multiple ... Expert insight into the recent approval of Cladribine for active relapsing multiple sclerosis. ...
more infohttps://reachmd.com/programs/global-neurology-academy/special-report-expert-opinion-new-ms-drug-approval/9794/

Cladribine injection for infusion - AHealthyMe - Blue Cross Blue Shield of MassachusettsCladribine injection for infusion - AHealthyMe - Blue Cross Blue Shield of Massachusetts

Cladribine injection for infusion. What is this medicine?. CLADRIBINE (KLA dri been) is a chemotherapy drug. This medicine ... an unusual or allergic reaction to cladribine, benzyl alcohol, other medicines, foods, dyes, or preservatives ...
more infohttp://www.ahealthyme.com/RelatedItems/121,572

cladribine : Information on Uses, Dosage & Side Effectscladribine : Information on Uses, Dosage & Side Effects

cladribine (generic name). Leustatin (brand name). This medicine reduces the growth of cancer cells and can suppress the immune ... CLADRIBINE (KLA dri been) is a chemotherapy drug. This medicine reduces the growth of cancer cells and can suppress the immune ... an unusual or allergic reaction to cladribine, benzyl alcohol, other medicines, foods, dyes, or preservatives ...
more infohttps://www.aarpmedicareplans.com/goldcontent/cladribine?brand=Leustatin

Cladribine (Intravenous route)Cladribine (Intravenous route)

There is no specific information comparing use of cladribine in children with use in other age groups. However, cladribine has ... Cladribine belongs to the group of medicines called antimetabolites. It is used to treat hairy cell leukemia, a cancer of the ... Cladribine may lower your bodys resistance and there is a chance you might get the infection the immunization is meant to ... Cladribine can temporarily lower the number of white blood cells in your blood, increasing the chance of getting an infection. ...
more infohttps://ssl.adam.com/content.aspx?productid=47&isarticlelink=false&pid=47&gid=600419&site=summithealth.adam.com&login=SUMM2111
  • Since 2017, cladribine is approved as an oral formulation (10 mg tablet) for the treatment of RRMS in Europe, UAE, Argentina, Chile, Canada and Australia. (wikipedia.org)
  • I ended up doing another round of cladribine in October 2017. (shift.ms)
  • Serious neurological toxicity (including irreversible paraparesis and quadriparesis) has been reported in patients who received cladribine injection by continuous infusion at high doses (4 to 9 times the recommended dose for hairy cell leukemia). (drugs.com)
  • Cladribine is given intravenously (into a vein) as a continous infusion over multiple days. (unm.edu)
  • Cladribine must be given slowly through an IV infusion, and you will receive it around the clock for 7 days in a row. (rxlist.com)
  • No dose-limiting toxicities were observed when beginning cladribine and rituximab on the same day, although most patients required short-term steroids to prevent and treat rituximab infusion reactions. (nih.gov)
  • The aims of this manuscript were to review the evidence for the efficacy and safety of cladribine in multiple sclerosis (MS) and to review the molecular and cellular mechanisms by which cladribine acts as a disease-modifying therapy in MS. (nih.gov)
  • You should use birth control to prevent pregnancy during each course of treatment with cladribine and for at least six months after your last dose of each treatment course. (medlineplus.gov)
  • If you are using hormonal (estrogen) contraceptives (birth control pills, patches, rings, implants, or injections) you should also use another method of birth control during each course of treatment with cladribine and for at least 4 weeks after your last dose of each treatment course. (medlineplus.gov)
  • If you are a male with a female partner who could become pregnant, be sure to use birth control during each course of treatment with cladribine and for at least six months after your last dose of each treatment course. (medlineplus.gov)
  • Suppression of bone marrow function, which is usually reversible and appears to be dose dependent, should be anticipated with cladribine. (drugs.com)
  • The specific dose and schedule of cladribine is dependent on many factors, including the medical condition being treated, the particular treatment regimen being utilized, the size of the patient, and the tolerance a patient has for therapy. (unm.edu)
  • The recommended dose of cladribine varies according to body weight. (pharmasave.com)
  • Cladribine is a prodrug and must be phosphorylated intracellularly to cladribine-monophosphate (MP) by the nuclear/cystosol enzyme deoxycytidine kinase (dCK) and the mitochondrial enzyme deoxyguanosine kinase. (diva-portal.org)
  • Deoxycytidine kinase phosphorylates cladribine to CdATP, which incorporates into DNA, leading to DNA strand breaks and inhibition of DNA synthesis. (clinicaltrials.gov)
  • Your doctor will order certain tests before, during, and after treatment to check your body's response to cladribine. (medlineplus.gov)
  • Do not take cladribine if you are pregnant or plan to become pregnant. (medlineplus.gov)
  • If you become pregnant while taking cladribine, stop taking cladribine and call your doctor immediately. (medlineplus.gov)
  • You should not become pregnant while you are receiving cladribine. (medlineplus.gov)
  • Do not use cladribine if you are pregnant. (rxlist.com)
  • Non-randomized arm: 20 with HCLv will begin rituximab with cladribine. (clinicaltrials.gov)
  • Rituximab has been found to increase the sensitivity of malignant cells to cladribine, suggesting that combination with cladribine might improve response in HCLv. (nih.gov)
  • Although cladribine alone lacks effectiveness for early or relapsed HCLv, cladribine with immediate rituximab achieves CRs without MRD and is feasible to administer. (nih.gov)
  • Simultaneous cladribine and rituximab might be superior or inferior to delaying rituximab until detection of MRD. (clinicaltrials.gov)
  • Clinical trial data argue strongly that cladribine is a safe and effective therapy for relapsing MS and that it may also be beneficial in progressive MS. The pharmacology of cladribine explains how it is selectively toxic towards lymphocytes. (nih.gov)
  • In the case of cladribine, there are no specific foods that you must exclude from your diet when receiving this medication. (rxwiki.com)
  • Cladribine may also be used for purposes not listed in this medication guide. (rxlist.com)
  • In comparison, in MS, cladribine is associated with a 6% rate of severe lymphocyte suppression (lymphopenia) (levels lower than 50% of normal). (wikipedia.org)
  • Immunophenotyping studies show that cladribine depletes lymphocyte populations in vivo with a predilection for B cells. (nih.gov)
  • Cladribine may cause side effects. (medlineplus.gov)
  • Although there is no specific information comparing use of cladribine in the elderly with use in other age groups, it is not expected to cause different side effects or problems in older people than it does in younger adults. (drugs.com)
  • You will be checked regularly by your doctor while you are taking Cladribine, to monitor side effects and check your response to therapy. (shift.ms)
  • Cladribine use can lead to serious side effects. (rxwiki.com)
  • Cladribine, unlike many other drugs, is toxic to both dividing and indolent lymphoid malignancies. (diva-portal.org)
  • In vitro studies demonstrate that cladribine also exerts immunomodulatory influences over innate and adaptive immunity. (nih.gov)
  • All available in vitro and clinical data on cladribine was undertaken. (diva-portal.org)
  • The mechanisms underlying cladribine resistance are multifactorial, e.g. decreased nucleoside transport, decreased activity or deficiency of dCK, altered intracellular pools of competing nucleotides, altered regulation of ribonucleotide reductase and increased drug inactivation by 5'-NT. (diva-portal.org)
  • This is not a complete list of cladribine drug interactions. (rxwiki.com)
  • The NHS in England are expected to provide funding for cladribine within three months of its approval, and the NHS in Wales must provide funding for the drug within two months. (mstrust.org.uk)
  • Cladribine is a disease modifying drug for people with relapsing remitting MS . It works by reducing the number of white blood cells, known as lymphocytes, which cause the nerve damage associated with MS. The drug is therefore able to slow down or stop the immune attack and reduce the damage to the brain and spinal cord. (mstrust.org.uk)
  • In the mid-1990s Buetler, in collaboration with Jack Sipe, a neurologist at Scripps, ran several clinical trials exploring the utility of cladribine in multiple sclerosis, based on the drug's immunosuppressive effects, Sipe's insight into MS, and Buetler's interest in MS due to his sister's having it. (wikipedia.org)
  • Cladribine is injected into a vein through an IV. (rxlist.com)
  • Cladribine may harm the fetus. (medlineplus.gov)
  • It is not known whether cladribine passes into breast milk or if it could harm a nursing baby. (rxlist.com)
  • Only 4 HCL-specific trials are listed on Cancer.gov: a phase II trial of cladribine followed 4 weeks later by 8 weekly doses of rituximab, and phase I-II trials of recombinant immunotoxins targeting CD22 (BL22, HA22) and CD25 (LMB-2). (clinicaltrials.gov)
  • In a phase III study, cladribine reduced relapses by 58% compared to placebo and also reduced the risk of disability progression. (mstrust.org.uk)
  • Ive searched the web and read articles around the trials with Cladribine and MS but would like to hear first hand if possible. (thisisms.com)
  • Unlike adenosine, cladribine has a chlorine molecule at position 2, which renders it partially resistant to breakdown by adenosine deaminase (ADA). (wikipedia.org)
  • Your doctor may tell you not to take cladribine. (medlineplus.gov)
  • Talk to your doctor about the risks of taking cladribine. (medlineplus.gov)
  • Cladribine is to be administered only by or under the immediate supervision of your doctor. (drugs.com)
  • To make sure cladribine is safe for you, tell your doctor if you have liver or kidney disease, or a bone marrow problem. (rxlist.com)
  • Cladribine: mechanisms and mysteries in multiple sclerosis. (nih.gov)
  • The purpose of this review was to elucidate and analyse the available data concerning mechanisms of resistance of cladribine with emphasis on recent advances in the characterization of activating and inactivating enzymes in the induction of resistance to cladribine. (diva-portal.org)
  • Cladribine may cause a severe decrease in the number of all types of blood cells in your blood. (medlineplus.gov)
  • Cladribine may cause severe nerve damage. (medlineplus.gov)
  • Cladribine is one of those therapies that is used when all others have been exhausted. (shift.ms)
  • When you are taking cladribine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. (drugs.com)
  • Using cladribine with any of the following medicines is not recommended. (drugs.com)
  • Using cladribine with any of the following medicines is usually not recommended, but may be required in some cases. (drugs.com)
  • Cladribine is currently being appraised by the Scottish Medicines Consortium (SMC) and we are contributing to the appraisal. (mstrust.org.uk)
  • Cladribine may increase the risk that you will develop cancer. (medlineplus.gov)
  • Cladribine produces its anti-cancer effects by inhibiting the ability of a cell to produce DNA or repair DNA. (unm.edu)
  • Cladribine fights cancer by preventing the growth of cancer cells, which eventually results in their destruction. (pharmasave.com)
  • As well as interfering with the genetic material DNA of cancer cells, cladribine can interfere with some of your normal cells. (pharmasave.com)
  • Cladribine treats a certain type of blood cancer. (rxwiki.com)
  • To determine if MRD levels and tumor markers (soluble CD25 and CD22) after cladribine and/or rituximab correlate with response and clinical endpoints. (clinicaltrials.gov)
  • Cladribine is a safe and effective form of induction therapy for relapsing MS. Its mechanism of benefit is not fully understood but the most striking action is selective, long-lasting, depletion of B lymphocytes with a particular predilection for memory B cells. (nih.gov)